Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial mesenchymal transition in vitro Lara Milian, Manuel Mata, Javier Alcacer, Marıa Oliver, Marıa Sancho-Tello, Jose Javier Martın de Llano, Carlos Camps, Jose Galbis, Julian Carretero, Carmen Carda PLoS ONE, 2020, 15, (2): e0228909. Doi : 10.1371/journal.pone.0228909 Abstract Background/Objective : Patients with non-small cell lung cancer (NSCLC) develop resistance to antitumor agents by mechanisms that involve the epithelial-to-mesenchymal transition (EMT). This necessitates the development of new complementary drugs, e.g., cannabinoid receptors (CB1 and CB2) agonists including tetrahydro-cannabinol (THC) and cannabidiol (CBD). The combined use of THC and CBD [...]
Lire la suiteCannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients Jeffrey Y. Hergenrather, Joshua Aviram, Yelena Vysotski, Salvatore Campisi-Pinto, Gil M. Lewitus and David Meiri. Rambam Maimonides Medical Journal, 2020, 11, (1), e0001 Doi : 10.5041/RMMJ.10384 Methods : Participants were adult patients licensed for medical cannabis (MC) treatment who also reported a diagnosis of ADHD by a physician. Data on demographics, ADHD, sleep, and anxiety were collected using self-report questionnaires. Data collected on MC treatment included administration route, cultivator, cultivar name, and monthly dose. Comparison statistics were used to evaluate differences in reported parameters between low (20–30 g, n=18) and [...]
Lire la suiteIs There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, Medscape, CME / ABIM MOC / CE Released : 12/13/2019 https://www.medscape.org/viewarticle/922367 Clinical Context The most common indication for the use of medicinal cannabis is pain, although the results of studies of cannabis products for chronic pain are mixed. Häuser and colleagues performed a review of systematic reviews of cannabis for chronic pain conditions, and their results were published in the October 15, 2017 issue of European Journal of Pain.[1] Reviewers evaluated 10 systematic reviews of cannabis for pain. Methodological quality was high in 4 of the reviews. There was [...]
Lire la suiteCannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Case Report Clarissa Laczkovics · Oswald D. Kothgassner · Anna Felnhofer · Claudia M. Klier Neuropsychiatrie, 2020, 4 p. Doi : 10.1007/s40211-020-00334-0 Summary In this report, we present a case of a 16,9- year-old patient with multiple substance use disorder (cannabis, MDMA, cocaine, ecstacy), severe depression, social phobia and narcissistic personality disorder. We administered Cannabidiol (CBD) capsules in different dosages (starting dosage 100 mg up to 600 mg over 8 weeks) after unsuccessful treatment with antidepressants. CBD was a safe and well tolerated medication for this patient. Upon treatment with CBD and [...]
Lire la suiteThe effects of cannabinoid 1 receptor compounds on memory : a meta-analysis and systematic review across species Faith Borgan, Katherine Beck, Emma Butler, Robert McCutcheon, Mattia Veronese, Anthony Vernon, Oliver D. Howes Psychopharmacology, 2019 Doi : 10.1007/s00213-019-05283-3 Abstract Rationale : While cannabis-based medicinal products have been shown to be effective for numerous neurological and psychiatric disorders, the evidence base regarding their adverse cognitive effects is poorly understood. The cannabinoid 1 receptor modulates memory performance via intracellular and extracellular mechanisms that alter synaptic transmission and plasticity. While previous literature has consistently shown that chronic cannabis users exhibitmarked cognitive impairments,mixed findings have been reported in the context [...]
Lire la suiteSpecies-specific susceptibility to cannabis-induced convulsions Benjamin J Whalley, Hong Lin, Lynne Bell, Thomas Hill, Amesha Patel, Roy A Gray, C Elizabeth Roberts, Orrin Devinsky, Michael Bazelot, Claire M Williams and Gary J Stephens British Journal of Pharmacology, 2018, 1-18. Doi : 10.1111/bph.14165 BACKGROUND AND PURPOSE Numerous claims are made for cannabis’ therapeutic utility upon human seizures, but concerns persist about risks. A potential confounder is the presence of both Δ9-tetrahydrocannabinol (THC), variously reported to be pro- and anticonvulsant, and cannabidiol (CBD), widely confirmed as anticonvulsant. Therefore, we investigated effects of prolonged exposure to different THC/CBD cannabis extracts on seizure activity and associated measures of endocannabinoid [...]
Lire la suiteCannabinoids in Pain Management and Palliative Medicine An Overview of Systematic Reviews and Prospective Observational Studies Winfried Häuser, Mary-Ann Fitzcharles, Lukas Radbruch, Frank Petzke The Deutsches Ärzteblatt International, 2017, 114, 627–634. Doi : 10.3238/arztebl.2017.0627 SUMMARY Background : There are conflicting interpretations of the evidence regarding the efficacy, tolerability, and safety of cannabinoids in pain management and palliative medicine. Methods : We conducted a systematic review (SR) of systematic reviews of randomized controlled trials (RCT) and prospective long-term observational studies of the use of cannabinoids in pain management and palliative medicine. Pertinent publications from January 2009 to January 2017 were retrieved by a selective search in the Cochrane [...]
Lire la suiteCannabis in Chinese Medicine : Are Some Traditional Indications Referenced in Ancient Literature Related to Cannabinoids? E. Joseph Brand and Zhongzhen Zhao Frontiers in Pharmacology, 2017, vol 8, Article 108, 1-11. doi : 10.3389/fphar.2017.00108 Cannabis sativa L. (Cannabaceae) has a long history of utilization as a fiber and seed crop in China, and its achenes (“seeds”) as well as other plant parts have been recorded in Chinese medical texts for nearly 2000 years. While the primary applications of cannabis in Chinese medicine center around the use of the achenes, ancient indications for the female inflorescence, and other plant parts include conditions such as pain [...]
Lire la suiteEuropean Commission proposes unified EU vote on WHO cannabis scheduling recommendations Published January 15, 2020 | By Alfredo Pascual https://mjbizdaily.com/european-commission-proposes-unified-eu-vote-on-who-cannabis-scheduling-recommendations/?utm_medium=email&utm_source=newsletter&utm_campaign=INTL_20200115_NEWS_Weekly In advance of the March session of the United Nations Commission on Narcotic Drugs (CND), the European Union’s executive branch has proposed that EU member nations vote in favor of three of the six World Health Organization (WHO) cannabis scheduling recommendations. The European Commission “Proposal for a Council Decision” is meaningful because – if adopted by the Council of Europe – the EU countries would vote as a block at the CND session in Vienna and the three motions [...]
Lire la suiteLe cannabidiol, un agent thérapeutique prometteur ? Benjamin Rolland , Mathieu Chappuy, Patrizia Carrieri SWAPS, 3e et 4e trimestre 2019, n° 92-93, , 5-6. Deuxième cannabinoïde le plus étudié après le THC, sans effet psychoactif, le cannabidiol dispose de propriétés thérapeutiques intéressantes, notamment en psychiatrie. Le point sur les recherches La grande famille des cannabinoïdes Les cannabinoïdes sont un ensemble de substances capables d’activer les récepteurs du même nom (« récepteurs cannabinoïdes »). Il existe deux grandes familles de récepteurs cannabinoïdes, CB1 et CB2. Dans le système nerveux central, c’est surtout CB1 qui est exprimé, alors que CB2 est principalement présent dans le système immunitaire. [...]
Lire la suite